Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC2 | Q92769 | 1/20 | 0.62 |
| ▸ | MAOB | P27338 | 6/20 | 0.59 |
| ▸ | MAOA | P21397 | 6/20 | 0.59 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.55 |
| ▸ | GPR183 | P32249 | 1/20 | 0.54 |
| ▸ | ACHE | P22303 | 1/20 | 0.52 |
| ▸ | ESR1 | P03372 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | NPC1 | O15118 | 2/20 | 0.49 |
| ▸ | RAB9A | P51151 | 2/20 | 0.49 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.47 |
| ▸ | MMP1 | P03956 | 1/20 | 0.47 |
| ▸ | MMP2 | P08253 | 1/20 | 0.47 |
| ▸ | MMP9 | P14780 | 1/20 | 0.47 |
| ▸ | EGFR | P00533 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13675782 | 0.90 | ESR1 (0.63) | HDAC2MAOBMAOATRPV1GPR183 | |
| SCHEMBL14566166 | 0.88 | HDAC2 (0.58) | HDAC2MAOBMAOAACHEMAPT | |
| SCHEMBL13675790 | 0.84 | MAOB (0.60) | HDAC2MAOBTRPV1ACHEESR1 | |
| SCHEMBL4003273 | 0.84 | TRPV1 (0.60) | HDAC2TRPV1MAPTRAB9A | |
| SCHEMBL4003267 | 0.84 | TRPV1 (0.60) | HDAC2TRPV1MAPTRAB9A | |
| SCHEMBL3445738 | 0.80 | HDAC2 (0.82) | HDAC2GPR183ACHE | |
| SCHEMBL3445735 | 0.80 | HDAC2 (0.82) | HDAC2GPR183ACHE | |
| SCHEMBL13675807 | 0.78 | TRPV1 (0.61) | HDAC2MAOBMAOATRPV1ACHE | |
| SCHEMBL13675794 | 0.78 | KDR (0.48) | HDAC2MAOBMAOAACHEMAPT | |
| SCHEMBL13675835 | 0.78 | TRPV1 (0.61) | HDAC2TRPV1ACHEMAPTNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090264424-A1 | VANILLOID RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS | AMGEN INC. | 2009-10-22 | — | — | US | disclosed |
| US-20090264424-A1 | VANILLOID RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS | AMGEN INC. | 2009-10-22 | — | — | US | disclosed |
| US-7582657-B2 | Treating inflammatory and neuropathic pain, headache, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, eye disorders, bladder disorders, psoriasis, skin disorders, asthma, herpes simplex | AMGEN INC. (US) | 2009-09-01 | — | — | US | disclosed |
| US-7582657-B2 | Treating inflammatory and neuropathic pain, headache, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, eye disorders, bladder disorders, psoriasis, skin disorders, asthma, herpes simplex | AMGEN INC. (US) | 2009-09-01 | — | — | US | disclosed |
| US-7579347-B2 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. (US) | 2009-08-25 | — | — | US | disclosed |
| US-7579347-B2 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. (US) | 2009-08-25 | — | — | US | disclosed |
| EP-1780196-A2 | Pyridine derivatives for use as vanilloid receptor ligands | Amgen, Inc (US) | 2007-05-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090264424-A1 | VANILLOID RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS | TRPV1, TRPV2, TRPV3 | HDAC2 892/4885MAOB 1152/4885MAOA 895/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.